Company ABIONYX Pharma Börse Stuttgart

Equities

609 FR0012616852

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Ratings for ABIONYX Pharma

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Börse Stuttgart Other stock markets 07:04:07 17/05/2024 pm IST			5-day change	1st Jan Change
1.032 ^EUR	-5.84%		+10.15%	-42.73%

14/03	Abionyx Pharma: to benefit from a 1ME grant from Bpifrance	CF
11/03	Abionyx: reduced net loss in 2023	CF

ABIONYX Pharma SA is specialized in research & development into HDL therapies (High Density lipoproteins) intended for the treatment of cardiovascular and metabolic disorders. HDLs, also known as good cholesterol, are fat and protein complexes that contribute to the transportation of cholesterol from the body's tissues to the liver and are linked to a decrease in the risk of atherosclerosis and coronary diseases.

At the end of 2023, the company boasted a portfolio of 3 products in clinical development.

Number of employees: 63

EUR in Million	2022	Weight	2023	Weight	Delta
Research 100.0 %	5	100.0 %	5	100.0 %	-11.65%

EUR in Million	2022	Weight	2023	Weight	Delta
France 100.0 %	5	100.0 %	5	100.0 %	-11.65%

Managers	Title	Age	Since
Cyrille Tupin CEO	Chief Executive Officer	48	01/07/01
Emmanuel de Fougeroux DFI	Director of Finance/CFO	-	01/08/01
Renee Benghozi CTO	Chief Tech/Sci/R&D Officer	-	09/15/09
Constance Keyserling COO	Chief Operating Officer	-	-
Laurent Guerci PRN	Corporate Officer/Principal	-	12/23/12

Members of the board	Title	Age	Since
Olivier Martinez BRD	Director/Board Member	54	-
Christian Chavy BRD	Director/Board Member	75	06/15/06
Cyrille Tupin CEO	Chief Executive Officer	48	01/07/01
Laura Coruzzi BRD	Director/Board Member	71	27/15/27
Karen Noël BRD	Director/Board Member	51	09/17/09
Emmanuel Huynh CHM	Chairman	54	26/19/26

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	32,459,012	22,076,290 ( 68.01 %)	253,928 ( 0.7823 %)	68.01 %

Name	Equities	%	Valuation
Cyrille Tupin 4.723 %	1,533,001	4.723 %	2 M €
Claresco Finance SA 0.0521 %	16,900	0.0521 %	18 974 €
UBS Asset Management France SA 0.0402 %	13,054	0.0402 %	14 656 €
Gestys SA 0.0308 %	10,000	0.0308 %	11 227 €
Rothschild & Co. Asset Management SCS 0.005053 %	1,640	0.005053 %	1 841 €
Allianz Global Investors GmbH (France) 0.002526 %	820	0.002526 %	921 €
Génération Vie SA 0.002234 %	725	0.002234 %	814 €

ABIONYX Pharma SA

33-43, avenue Georges Pompidou Bâtiment D2

31130, Balma

+33 5 62 24 97 06

http://www.abionyx.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.09 EUR

Average target price

10.5 EUR

Spread / Average Target

+863.30%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	114B
REGENERON PHARMACEUTICALS, INC.	+11.84%	104B
BIONTECH SE	-14.15%	22.41B
ARGENX SE	-1.05%	22.28B
GENMAB A/S	-5.29%	19.07B
WUXI APPTEC CO., LTD.	-38.29%	18B
BEIGENE, LTD.	-4.16%	17.89B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.28B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.55B

Bio Therapeutic Drugs